TrialClinical cancer research : an official journal of the American Association for Cancer Research2024

FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma.

Kavita Natrajan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.